The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011.
Sean Whittaker
Consultant or Advisory Role - Millennium; Novartis; Roche
Honoraria - Celgene
Research Funding - Gloucester Pharmaceuticals
Expert Testimony - Merck
Pablo L. Ortiz-Romero
No relevant relationships to disclose
Reinhard Dummer
No relevant relationships to disclose
Annamari Ranki
No relevant relationships to disclose
Baktiar Hasan
No relevant relationships to disclose
Bart Meulemans
No relevant relationships to disclose
Sylke Gellrich
No relevant relationships to disclose
Robert Knobler
Consultant or Advisory Role - Therakos
Honoraria - Therakos
Rudolf Stadler
Consultant or Advisory Role - Roche
Honoraria - Roche
Matthias Karrasch
No relevant relationships to disclose
Emad Shash
No relevant relationships to disclose